【优质】TheOphthalmicPharmaceuticalMarketOutlookto2016.pptVIP

R E L A T E D R E P O R T S: Please refer to the back of this pack for a list of related titles R E L A T E D R E P O R T S: Please refer to the back of this pack for a list of related titles ! Author: Experience: Companies: Qualifications: Expertise: Companies profiled: Reference Code: Publication Date: Full report: Module: Regions/countries: R E L A T E D R E P O R T S: Please refer to the back of this pack for a list of related titles R E L A T E D R E P O R T S: Please refer to the back of this pack for a list of related titles ! Indications covered: Companies profiled: Reference Code: Publication Date: Full report: Module: Regions/countries: Related Reports The Ophthalmic Pharmaceutical Market Outlook to 2016 Competitive landscape, pipeline analysis, and growth opportunities BI00042-019 September 2011 118 pages ,11 figures, 20 tables Markets Therapies US 5EU Japan Allergan Novartis Merck Co. Pfizer Santen Pharmaceutical ISTA Pharmaceuticals Glaucoma Dry eye syndrome Age-related macular degeneration Diabetic retinopathy Diabetic macular edema Xalatan/Xalacom declining but will maintain the top spot to 2016 Patents on most of the leading brands in the ophthalmic market have either already expired or are expected to do to by 2012 Xalatan, Lumigan and Alphagan will all decline rapidly in the face of patent expiries to 2016 Saflutan sales are forecast to grow strongly, exceeding $400m by 2016 Retinal diseases are the fastest growing segment The ophthalmic market will grow steadily at a CAGR of 4.6%, reaching $21.1bn in 2016 Glaucoma is the largest market segment with 2010 sales of $5.5bn, accounting for 35% of the market Despite increasing prevalence, the glaucoma market will grow slowly to 2016 Artificial tears and anti-infectives will show static sales over the forecast period Ch 2. Glaucoma Sec: Epidemiology; Market landscape; Forecast of key products Source: Company reports, Business Insights Aging population and obesity to